文献速递淋巴瘤白血病

毛细胞白血病的基因组学

Genomics of Hairy Cell Leukemia.
PubMed 文献 · J Clin Oncol · 2017-02-13

毛细胞白血病(HCL)是一种慢性成熟B细胞肿瘤,几乎所有患者存在BRAF-V600E激活性突变,该突变塑造了HCL的关键生物学特征。16%患者伴KLF2或CDKN1B/p27突变,可能协同致病。BRAF-V600E检测可用于HCL与HCL样肿瘤的遗传学鉴别诊断,口服BRAF抑制剂维莫非尼在多重复发或难治患者中短程治疗产生近100%缓解率。

要点

  • BRAF-V600E突变几乎存在于所有HCL患者整个疾病谱和临床过程中。
  • 16%的HCL患者伴有KLF2或CDKN1B/p27伴随突变。
  • 维莫非尼短程治疗多重复发或难治HCL的缓解率近100%,完全缓解率35%–42%,无骨髓毒性。

核心结论

  • BRAF-V600E是HCL的遗传学病因,检测该突变可实现HCL与HCL样肿瘤的遗传学鉴别诊断,并作为新的治疗靶点。
  • 维莫非尼在多重复发或嘌呤类似物难治HCL患者中短程治疗产生近100%缓解率,包括35%–42%的完全缓解率,且无骨髓毒性。

研究设计与样本

  • 综述总结了HCL的基因组学发现及BRAF抑制剂维莫非尼的临床试验结果。

主要发现

  • BRAF-V600E激活性突变在几乎全部HCL患者中体细胞克隆性存在,贯穿整个疾病谱和临床过程。
  • BRAF-V600E通过异常激活RAF-MEK-ERK信号通路塑造HCL的关键生物学特征,包括特异性表达签名、毛样形态和抗凋亡行为。
  • KLF2转录因子或CDKN1B/p27细胞周期抑制剂的伴随突变在16%的HCL患者中反复出现,可能与BRAF-V600E协同参与HCL发病。
  • BRAF-V600E在包括HCL变异型和脾边缘区淋巴瘤在内的其他B细胞肿瘤中缺失,检测该突变可在常规血样中无创地进行遗传学鉴别诊断。
  • 维莫非尼在多重复发或嘌呤类似物难治HCL患者的临床试验中产生近100%的缓解率,完全缓解率35%–42%,无骨髓毒性。

关键数值与推荐

  • HCL患者中KLF2或CDKN1B/p27伴随突变频率为16%。
  • 维莫非尼治疗多重复发或嘌呤类似物难治HCL的缓解率近100%,完全缓解率35%–42%,无骨髓毒性。

临床怎么用

  • BRAF-V600E检测可用于HCL与HCL样肿瘤的遗传学鉴别诊断,甚至可在常规血样中无创进行。
  • 对于嘌呤类似物治疗后多重复发或难治的HCL患者,短程口服BRAF抑制剂维莫非尼是一种治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hairy cell leukemia (HCL) is a chronic mature B-cell neoplasm with unique clinicopathologic features and an initial exquisite sensitivity to chemotherapy with purine analogs; however, the disease relapses, often repeatedly. The enigmatic pathogenesis of HCL was recently clarified by the discovery of its underlying genetic cause, the BRAF-V600E kinase-activating mutation, which is somatically and clonally present in almost all patients through the entire disease spectrum and clinical course. By aberrantly activating the RAF-MEK-ERK signaling pathway, BRAF-V600E shapes key biologic features of HCL, including its specific expression signature, hairy morphology, and antiapoptotic behavior. Accompanying mutations of the KLF2 transcription factor or the CDKN1B/p27 cell cycle inhibitor are recurrent in 16% of patients with HCL and likely cooperate with BRAF-V600E in HCL pathogenesis. Conversely, BRAF-V600E is absent in other B-cell neoplasms, including mimickers of HCL that require different treatments (eg, HCL-variant and splenic marginal zone lymphoma). Thus, testing for BRAF-V600E allows for a genetics-based differential diagnosis between HCL and HCL-like tumors, even noninvasively in routine blood samples. BRAF-V600E also represents a new therapeutic target. Patients' leukemic cells exposed ex vivo to BRAF inhibitors are spoiled of their HCL identity and then undergo apoptosis. In clinical trials of patients with HCL who have experienced multiple relapses after purine analogs or who are refractory to purine analogs, a short course of the oral BRAF inhibitor vemurafenib produced an almost 100% response rate, including complete remission rates of 35% to 42%, without myelotoxicity. To further improve on these results, it will be important to clarify the mechanisms of incomplete leukemic cell eradication by vemurafenib and to explore chemotherapy-free combinations of a BRAF inhibitor with other targeted agents (eg, a MEK inhibitor and/or an anti-CD20 monoclonal antibody).

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Tiacci E, Pettirossi V, Schiavoni G, et al. Genomics of Hairy Cell Leukemia. J Clin Oncol. 2017. PMID: 28297625. doi:10.1200/JCO.2016.71.1556

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。